Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond.
Saghir Ali, Xiaochen Tian, Kathryn A. Cunningham, Jia Zhou
J Med Chem May 1, 2025 DOI: 10.1021/acs.jmedchem.5c01156 via PubMed Central
Summary
AI-generated from the abstractThe 5-HT2A receptor is a key target for psychedelic drugs, and research is exploring its role in developing new treatments for psychiatric disorders. This review examines the receptor's structure, function, and signaling pathways, highlighting how psychedelics like psilocybin and LSD interact with it to produce their effects. The authors discuss potential therapeutic applications beyond psychedelic experiences, including for depression, anxiety, and addiction, while also considering the challenges of designing drugs that retain therapeutic benefits without hallucinogenic side effects. The work synthesizes current knowledge on 5-HT2A receptor pharmacology and its implications for drug development.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Citations | 5 |
| Key finding | The 5-HT2A receptor is a promising target for developing psychedelic drugs and potential treatments for psychiatric disorders, though separating therapeutic from hallucinogenic effects remains a challenge. |
Abstract
Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond.